Lilly sues six over black-market retatrutide
Analysis based on 10 articles · First reported Aug 12, 2026 · Last updated Aug 13, 2026
The lawsuits reinforce Lilly's efforts to protect its intellectual property and market position in the obesity drug space, potentially deterring black-market sales. The delay in FDA submission may temper near-term revenue expectations, but the strong clinical data and early access program support long-term growth prospects.
Eli Lilly and Company filed six lawsuits against U.S. companies accused of illegally selling black-market versions of its experimental obesity drug retatrutide. The defendants include compounding pharmacies, medical spas, and online sellers: Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co. Retatrutide is in Phase 3 clinical trials and has not been approved by any regulator. The U.S. United States — Food and Drug Administration stated in June that sales of unapproved retatrutide and other GLP-1 products are illegal and cannot lawfully be compounded. Lilly has referred over 200 individuals and entities to the FDA, the U.S. Department of Justice, state attorneys general, and law enforcement. It also reported more than 14,000 unlawful listings to platforms. United States — United States Customs and Border Protection intercepted over 690 shipments of illicit GLP-1 drugs in fiscal 2025, with July seizures more than doubling. Lilly delayed its FDA submission for retatrutide to Q1 2027 and allowed limited early access for certain patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard